CARDIO-TTTransform: the establishment of a long-duration franchise

Research evidence excerpt

CARDIO-TTTransform: the establishment of a long-duration franchise

UK | Pharmaceuticals

AstraZeneca PLC EquityJuneResearch26, 2026

FLASH NOTECARDIO-TTRansform: the establishment of a

RATING BUYlong-duration franchise

PRICE 13,910.00p^

In this video, we outline why upcoming CARDIO-TTRansform P3 data

(2H26) is a key catalyst, with a trial that could show meaningful benefit PRICE TARGET | % TO PT 18,000.00p | +29%

on top of standard of care. If successful, this supports a multi-billion- 52W HIGH-LOW 15,732p - 10,103p

$ opportunity in an underpenetrated market, with a positive read-out FLOAT (%) | ADV MM (USD) 96.6% | 373.44

potentially de-risking $5bn in sales and adding low-s.d.% to NPV. The story MARKET CAP £215.7B | $283.7B

extends beyond a single readout, with AZN building a multi-mechanism TICKER AZN LN ^Prior trading day's closing price unless otherwise

franchise across silencers & depleters. noted.

RATING BUY

TICKER AZN

PRICE $183.02^

PRICE TARGET | % TO PT $245.00 | +34%

.

The ATTR market is set to reach c.$18bn by 2030: Transthyretin amyloidosis (ATTR) is an

increasingly important and rapidly evolving disease area, shifting from late-stage palliative

care to earlier diagnosis and the development of effective disease-modifying therapies. Once

considered rare, ATTR is now recognized as significantly more prevalent, particularly among

older populations, yet remains underdiagnosed and undertreated, with the majority of patients

still not receiving therapy today. This presents a substantial commercial opportunity, as

improved awareness, non-invasive diagnostic tools, and expanding treatment options, ranging

from protein stabilizers and silencers to emerging gene editing and amyloid-clearing therapies,